Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Pilot Study of Hydroxychloroquine for the Treatment of AIMSS (AIMSS)

7 november 2026 bijgewerkt door: Tarah J Ballinger, MD, Indiana University

A Phase II Single-Arm Pilot Study of Hydroxychloroquine for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome

The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase Inhibitor Associated Musculoskeletal Syndrome (AIMSS) for patients with breast cancer.

Studie Overzicht

Gedetailleerde beschrijving

Aromatase Inhibitor (AI) therapy is highly effective for post-menopausal, estrogen receptor (ER) positive breast cancer, yet the clinical effectiveness of AI therapy is limited by noncompliance and early treatment discontinuation due to musculoskeletal side effects, which include joint pain, joint stiffness, bone pain, muscle weakness, and myalgias. Methods to improve compliance to AI therapy have the potential to increase survival.

This study will look at hydroxychloroquine (HCQ), a disease-modifying antirheumatic drug (DMARD) with well-established anti-inflammatory and immunomodulatory properties. It is FDA-approved for the treatment of conditions characterized by chronic inflammatory joint pain similar to AIMSS. This single-arm, proof of concept study will look for an improvement in joint pain for patients undergoing standard of care treatment involving AI therapy.

Studietype

Ingrijpend

Inschrijving (Geschat)

35

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Niraj Shah, MS
  • Telefoonnummer: 317-278-3420
  • E-mail: shahnir@iu.edu

Studie Locaties

    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Werving
        • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
        • Hoofdonderzoeker:
          • Tarah Ballinger, MD
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Age ≥ 18 years at the time of informed consent

  2. Ability to provide written informed consent and HIPAA authorization

  3. Diagnosis of DCIS or stage I, II, or III breast cancer

  4. Currently receiving adjuvant aromatase inhibitor therapy (anastrozole, letrozole or exemestane) for ≥ 4 weeks prior to enrollment Note: Concurrent use of ovarian suppression is allowed Note: Concurrent use of CDK4/6 inhibitors is not allowed due to cytopenia risk

  5. New or worsening self-reported musculoskeletal pain that began or significantly worsened after initiation of AI therapy

  6. BPI average pain score of ≥ 4 during screening

  7. ECOG PS 0-2

  8. Adequate organ function:

    1. Absolute neutrophil count ≥1,500/µL
    2. Hemoglobin ≥11.0 g/dL
    3. Platelet count ≥100,000/µL
    4. Serum creatinine ≤1.5× upper limit of normal (ULN) or eGFR ≥60 mL/min/1.73m2
    5. Total bilirubin ≤1.5× ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)
    6. AST and ALT ≤1.5× ULN
  9. Must agree to maintain stable doses of any analgesic medications or other AIMSS related therapies during the study period Note: rescue doses of acetaminophen or ibuprofen allowed on a non-daily basis, unless not new

Exclusion Criteria:

  1. Current or prior use of hydroxychloroquine or chloroquine within 6 months
  2. Known hypersensitivity to hydroxychloroquine, chloroquine, or 4-aminoquinoline compounds
  3. History of retinopathy or retinal vein occlusion issues Note: While there is an association between retinopathy and HCQ use, this occurs rarely and with long term use with higher cumulative doses that used here. Other clinical trials have not required retinal exam (example: CTO-TBCRC04627, approved by IU IRB)
  4. History of congestive heart failure (any NYHA class)
  5. QTc prolongation (>450 msec) at screening or history of significant arrhythmias requiring treatment
  6. Moderate to severe renal impairment (eGFR <60 mL/min/1.73m2)
  7. Use of a prohibited concomitant medication (refer to Section 6.3.2) that cannot be discontinued or changed to an alternate therapy
  8. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency
  9. History of porphyria
  10. History of psoriasis
  11. History of antiepileptic medications
  12. Known history of inflammatory arthritis (example: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) or connective tissue disease (example: systemic lupus erythematosus, scleroderma, polymyositis)
  13. Recent initiation or dose change (within 4 weeks) of medications for pain management (NSAIDs, duloxetine, gabapentin, pregabalin, opioids) Note: Patients on stable doses for >4 weeks are eligible
  14. Patients currently receiving or planned to receive high dose systemic treatment with corticosteroids defined as: cortisone >50mg; hydrocortisone >40mg, prednisone >10mg, methylprednisolone >8mg or dexamethasone >1.5mg; or another immunosuppressive agent Note: Topical or inhaled corticosteroids are allowed
  15. Other active malignancy other than breast cancer requiring systemic therapy
  16. Pregnant or lactating
  17. Co-enrollment in another clinical trial Note: Patients may co-enroll in other clinical trial(s) if the trial(s) does not interfere with the objectives of this trial
  18. Significant psychiatric illness, in the opinion of the investigator, that would limit compliance with study requirements
  19. Any active suicidality or history of active suicidal ideation/behavior/attempt within 1 year prior to screening
  20. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Hydroxychloroquine sulfate

Hydroxychloroquine sulfate, 400 mg orally once daily

Drug: Hydroxychloroquine sulfate Dose: 400 mg orally once daily Duration: 12 weeks

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To evaluate the efficacy of hydroxychloroquine
Tijdsspanne: Day 1 and Week 12

To evaluate the efficacy of hydroxychloroquine 400 mg daily in reducing joint pain associated with AIMSS as measured by change in Brief Pain Inventory (BPI) Average Pain score (scored from 0-10; a minimally important difference is a 2-point reduction or 30% from baseline).

Day 1 and Week 12

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of patients achieving a clinically meaningful improvement
Tijdsspanne: Day 1 and Week 12

To assess the proportion of patients achieving a clinically meaningful improvement (≥2-point reduction) in BPI Average Pain score.

Day 1 and Week 12
Changes in BPI Worst Pain and Pain Interference scores
Tijdsspanne: Day 1 and Week 12

To evaluate changes in BPI Worst Pain and Pain Interference scores (scored from 0-10; a minimally important difference is a 2-point reduction or 30% from baseline).

Day 1 and Week 12
Changes in endocrine therapy related quality of life
Tijdsspanne: Day 1 and Week 12

To assess changes in endocrine therapy related quality of life by FACT-ES (5 point Likert-type scale).

Day 1 and Week 12
Changes in grip strength
Tijdsspanne: Day 1 and Week 12

To assess changes in grip strength as an objective measure of function using Jamar hand dynamometers (scale of 0-200lbs).

Day 1 and Week 12
Patient-reported global impression of change
Tijdsspanne: Week 12

To evaluate patient-reported global impression of change using the Patient Global Impression of Change (PGIC) (scale 0-6, 6 being the worst outcome).

Week 12
Safety of hydroxychloroquine in this patient population
Tijdsspanne: Day 1, Week 4, Week 12, 30 days post EOT

To assess safety of hydroxychloroquine in this patient population using NCI CTCAE v5.0 (grade 1-5, 5 being the worst outcome).

Day 1, Week 4, Week 12, 30 days post EOT
Tolerability of hydroxychloroquine in this patient population
Tijdsspanne: Day 1, Week 4, Week 12, 30 days post EOT

To assess tolerability of hydroxychloroquine in this patient population via number of patients who completed treatment.

Day 1, Week 4, Week 12, 30 days post EOT
Adherence to aromatase inhibitor therapy
Tijdsspanne: Screening, Day 1, and Week 12

To evaluate adherence to aromatase inhibitor therapy during the study period via number of patients who completed treatment based on self-report.

Screening, Day 1, and Week 12

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Tarah Ballinger, MD, IUSCCC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

19 oktober 2026

Primaire voltooiing (Geschat)

1 december 2029

Studie voltooiing (Geschat)

1 december 2029

Studieregistratiedata

Eerst ingediend

25 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 september 2026

Eerst geplaatst (Werkelijk)

17 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

7 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren